Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial | Synapse

May 10, 2005

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Key Points

Key points are not available for this paper at this time.

Abstract

Although interrupted, this trial provides an indication that Abeta immunotherapy may be useful in Alzheimer disease.

Mark Helpful

Bookmark

Relay

Mark Helpful

Bookmark

Relay

Cite This Study

Gilman et al. (Tue,) studied this question.

synapsesocial.com/papers/69d6ca7d639f29d8dcab3387 https://doi.org/https://doi.org/10.1212/01.wnl.0000159740.16984.3c

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD2005 · 351 citations
2The Clinical Dementia Rating (CDR)1993 · 9,933 citations
3A new rating scale for Alzheimer's disease1984 · 4,191 citations
4Pubertal Changes in Biochemical Markers of Growth2003 · 103 citations
5Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization2003 · 1,342 citations